|
|
Sacramento selected as COVID-19 vaccine trial site
UC Davis, Kaiser partnering with Pfizer
萨克拉门托被选为COVID-19疫苗试验地点
加州大学戴维斯分校，凯泽和辉瑞合作
(KCRA3)Sacramento has been selected as a site for a COVID-19 vaccine trial. Both UC Davis Medical Center and Kaiser Permanente are participating in the vaccine trial through a partnership with Pfizer.
萨克拉门托已被选为COVID-19疫苗试验的地点。加州大学戴维斯医学中心和凯萨医疗机构都通过与辉瑞的合作参与了疫苗试验。
The trial will span 120 locations with a goal of including 30,000 applicants worldwide.
该试验将在120个地点进行，目标是在全球范围内吸引3万名申请者。
“What we want the community to know is that this is really important research. It’s a first step in developing a vaccine for COVID,” UC Davis Medical School Dean Allison Brashear said.
“我们想让公众知道的是，这是一项非常重要的研究。这是开发COVID疫苗的第一步，”加州大学戴维斯医学院院长Allison Brashear说。
UC Davis Medical Center explained it is focusing on enrolling participants who are Latinx and Black -- communities disproportionately affected by COVID-19.
加州大学戴维斯分校医学中心解释说，该中心的重点是招收拉丁裔和黑人参与者，他们是受COVID-19影响最严重的社区。
“Anybody 18 to 55 is in the first group and then shortly thereafter it will be individuals over 55. And, we want people who are reasonably healthy,” Brashear explained.
他说:“任何18到55岁的人都属于第一类，之后不久就会有55岁以上的人。而且，我们需要的是相当健康的人。
Kaiser Permanente is looking for applicants who are between 18 to 85 years old and generally healthy but are considered high-risk due to employment, a living situation or being part of a community considered at-risk for COVID-19.
Kaiser Permanente正在寻找年龄在18岁至85岁之间的申请者，他们一般健康，但由于工作、生活条件或属于可能感染COVID-19的社区而被认为是高危人群。
“We’re not injecting any of the viral proteins themselves. We aren’t injecting any of the virus into individuals,” said Nicola Klein, with Kaiser Permanente Vaccine Study Center. “But the MRNA -- what’s called nucleic acid technology MRNA -- and that includes DNA vaccines, which you may have also heard about. This is a new technology for vaccine. There are no currently licensed vaccines that are developed using this technology. But, it is the genetic material. It can’t replicate on its own or do anything by itself.”
“我们没有注射任何病毒蛋白本身。Kaiser Permanente疫苗研究中心的Nicola Klein说:“我们不会向人体注射任何病毒。”“但是MRNA——被称为核酸技术MRNA——包括DNA疫苗，你可能也听说过。这是一种新的疫苗技术。目前还没有使用该技术开发的获得许可的疫苗。但是，它是遗传物质。它不能自己复制，也不能自己做任何事情。”
Kaiser Permanente is also part of another COVID-19 vaccine trial, co-developed by the National Institute of Allergy and Infectious Diseases and Moderna.
Kaiser Permanente还参与了另一项COVID-19疫苗试验，由美国国家过敏和传染病研究所(National Institute of Allergy and Infectious Diseases)和Moderna联合开发。
UC Davis explained if the vaccine candidate’s success continues, regulatory review can happen as early as October.
加州大学戴维斯分校解释说，如果候选疫苗继续取得成功，监管审查最早将于10月进行。
If approved, Pfizer and BioNTech plan to supply up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021.
如果获得批准，辉瑞和BioNTech计划在2020年底前供应1亿剂，到2021年底供应约13亿剂。
联系人:-
电话号码: |
|
发表于 2020-8-13 14:00:34
发表于 2022-12-30 09:40:08